These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 26232113)

  • 21. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases.
    Smith Sehdev AE; Sehdev PS; Kurman RJ
    Am J Surg Pathol; 2003 Jun; 27(6):725-36. PubMed ID: 12766576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
    Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
    J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
    Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
    Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
    Vang R; Shih IeM; Kurman RJ
    Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
    Ho CL; Kurman RJ; Dehari R; Wang TL; Shih IeM
    Cancer Res; 2004 Oct; 64(19):6915-8. PubMed ID: 15466181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
    Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
    Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
    J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
    Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
    Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
    Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
    Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
    Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
    J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
    Vang R; Shih IeM; Kurman RJ
    Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diverse tumorigenic pathways in ovarian serous carcinoma.
    Singer G; Kurman RJ; Chang HW; Cho SK; Shih IeM
    Am J Pathol; 2002 Apr; 160(4):1223-8. PubMed ID: 11943707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
    Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
    Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
    Kurman RJ
    Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
    Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.